(Q45421221)

14 December 2017

Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine (English)

1 reference

14 December 2017

1 reference

5

1 reference

14 December 2017

2

Allan Hildesheim

1 reference

14 December 2017

7

Ligia A Pinto

1 reference

14 December 2017

Alfonso J García-Piñeres

1

1 reference

14 December 2017

Matthew Trivett

3

1 reference

14 December 2017

Marcus Williams

4

1 reference

14 December 2017

Vineet N Kewalramani

6

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

European Journal of Immunology

14 December 2017

1 reference

14 December 2017

36

1 reference

14 December 2017

2

1 reference

14 December 2017

437-445

1 reference

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses

14 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN: a guide to some mysteries of dendritic cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Human Cytomegalovirus Binding to DC-SIGN Is Required for Dendritic Cell Infection and Target Cell trans-Infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Mycobacteria target DC-SIGN to suppress dendritic cell function

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Papillomavirus-like particle based vaccines: cervical cancer and beyond

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Papillomaviruses infect cells via a clathrin-dependent pathway

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Physical interaction of human papillomavirus virus-like particles with immune cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Papillomavirus-like particles induce acute activation of dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

DC-SIGN, but not sDC-SIGN, can modulate IL-2 production from PMA- and anti-CD3-stimulated primary human CD4 T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535068

7 January 2021

Identifiers

DOI

10.1002/EJI.200535068

1 reference

14 December 2017

1 reference